Seeking Alpha EN

Phathom Pharmaceuticals Non-GAAP EPS of -$0.08 beats by $0.11, revenue of $57.6M beats by $0.16M

Feb 26, 2026 &02202626202628; 12:20 UTC seekingalpha.com Trending 3/5

Read original on seekingalpha.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Phathom Pharmaceuticals ha superato le stime sia per l'EPS non-GAAP (-$0,08 vs -$0,19 atteso) che per i ricavi ($57,6M vs $57,44M atteso). Questo risultato positivo potrebbe sostenere il prezzo delle azioni a breve termine, indicando una potenziale trazione commerciale per i suoi prodotti.

AI CONFIDENCE

0% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

PHAT

PHATStock

Expected to rise

Battuto sia le stime EPS che ricavi, indicando performance operativa migliore del previsto

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Considerare posizioni long a breve termine, con attenzione alla volatilità tipica del settore biotech. Monitorare i volumi di trading per confermare l'interesse del mercato.

KEY SIGNALS

EPS non-GAAP di -$0,08 batte di $0,11Ricavi di $57,6M battono di $0,16M

SECTORS INVOLVED

SanitarioFarmaceutico

Analysis generated on Feb 26, 2026 at 20:47 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Phathom Pharmaceuticals Non-GAAP EPS of -$0.08 beats by $0.11, revenue of $57.6M beats by $0.16M

RELATED INTELLIGENCE